Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Because it is not FDA-approved, it cannot be legally manufactured, marketed, sold, or prescribed in the United States outside of a registered clinical trial
GLP-1 Agonists - Drug Pipeline Therapeutic Assessment This section of the report covers the analysis of GLP-1 agonists drug candidates based on several segmentations, including: By Phase Late-Stage Products (Phase 3 and Phase 4) Mid-Stage Products (Phase 2) Early-Stage Products (Phase I) Preclinical and Discovery Stage Products By Drug Class Peptides Small Molecules mRNA-based Therapies Antibody-Based Therapies By Route of Administration Oral Parenteral Others GLP-1 Agonists - Pipeline Assessment Segmentation, By Phases The report covers phase I, phase II, phase III, phase IV, and early-phase drugs
Indian J Gastroenterol 2025
The CDC classifies someone as overweight if they have a BMI of 25.0 to 29.9, and obese if they have a BMI of 30.0 or greater
B.BlankM
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
US$ 29.28
US$ 21.85
US$ 27.98
US$ 26.11
US$ 29.17
US$ 26.05
US$ 29.17
